Helzlsouer K J, Huang H Y, Strickland P T, Hoffman S, Alberg A J, Comstock G W, Bell D A
Department of Epidemiology, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, Maryland 21205, USA.
Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):945-9.
A nested case-control study was conducted to determine whether a genetic polymorphism in the CYP17 gene, which encodes for an enzyme that mediates steroid hormone metabolism, was associated with an increased risk of breast cancer. No association was found between the presence of an A2 allele and the subsequent development of breast cancer [A1/A2 odds ratio, 0.61 (95% confidence interval, 0.33-1.14); A2/A2 odds ratio, 0.89 (95% confidence interval, 0.41-1.95)]. No significant association was observed with risk factors presumed to be surrogates for endogenous estrogen exposure, nor was there an association observed with the stage of disease at diagnosis. Genotype frequencies in this Caucasian population were similar to those reported for African-American, Asian, and Latino women. Additional studies of larger size are needed to achieve a consensus regarding the relevance of CYP17 genotypes to the risk of developing breast cancer.
开展了一项巢式病例对照研究，以确定编码介导类固醇激素代谢的一种酶的CYP17基因中的基因多态性是否与乳腺癌风险增加相关。未发现A2等位基因的存在与随后发生的乳腺癌之间存在关联[A1/A2比值比，0.61（95%置信区间，0.33 - 1.14）；A2/A2比值比，0.89（95%置信区间，0.41 - 1.95）]。未观察到与被认为是内源性雌激素暴露替代指标的危险因素存在显著关联，也未观察到与诊断时的疾病分期存在关联。该白种人群中的基因型频率与非裔美国、亚洲和拉丁裔女性报告的频率相似。需要开展更大规模的进一步研究，以就CYP17基因型与患乳腺癌风险的相关性达成共识。
